Researchers create AERSMine to aid analysis of FDA adverse event data

Data

A team at Cincinnati Children's Hospital Medical Center has created a tool to improve analysis of adverse event data gathered by FDA. The web-based system, AERSMine, is designed to make it easier to dig deep into the data in search of evidence of unexpected harms caused by FDA-approved drugs when given in isolation or alongside other medications.

FDA releases data from its repository of adverse event reports every quarter, but the information is impossible to probe without knowing how to create relational databases. This limits the ability of physicians, researchers and the public to sift through the data in search of trends of relevance to their interests.

Third parties, such as FDAble, have designed systems that make it trivial to search for cases relating to different drugs and the companies that manufacture them, but the team at Cincinnati Children's Division of Biomedical Informatics and the Clinical and Translational Sciences Program thinks there is scope to create more powerful analytical tools.

WEBINAR

Webinar: The Key to Continuous Compliance for Medical Device Software Developers

Risk is not an option in medical device software development. You need to mitigate time-to-market, FDA, and security risks, or you could be facing a costly recall or software update. Attend this webinar to learn how to use static analysis to ensure continuous compliance with industry standards and regulatory requirements, improve security for increasingly connected medical devices, and enforce corporate and industry coding rules and best practices.

"One of the capabilities that makes AERSMine different from any other clinical data mining system is its ability to use knowledge frameworks--ontologies--to form the groupings of patients, medications, and outcomes and gain what we believe is an unprecedented power to explore and identify both unexpectedly negative and positive drug effects. Doing this has the potential to uncover new uses for drugs and drug regimen combinations," Bruce Aronow, co-director of the Computational Medicine Center at Cincinnati Children's, said in a statement.

Aronow is also senior study author on a paper published in the journal Nature Biotechnology describing AERSMine. The system supports searches that both include and exclude multiple different drugs, indications and types of adverse event. Users can filter the output of these searches by age group and gender. By providing these search capabilities--and enabling users to visualize the output--the team members think they can improve the utility of data in FDA’s Adverse Event Reporting System.

- read the release

Related Article:
FDA study spanks drugmakers for poor adverse events reporting

 

Suggested Articles

Aldeyra Therapeutics aced a phase 3 trial of reproxalap for allergic conjunctivitis, sending its stock up at least 66% in premarket trading.

California data analytics company Saama Technologies has raised $40 million as it looks to bolster its artificial technology platform to “disrupt” clinical…

Illumina plans to help map thousands of years of DNA fragments in a hunt for clues into today’s mental health issues and neurological conditions.